ENZY BTA Stock Overview
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enzymatica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.25 |
| 52 Week High | kr3.50 |
| 52 Week Low | kr2.97 |
| Beta | -0.072 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENZY BTA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 8.0% | -5.7% | -1.6% |
| 1Y | n/a | 58.1% | 7.8% |
Return vs Industry: Insufficient data to determine how ENZY BTA performed against the Swedish Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ENZY BTA performed against the Swedish Market.
Price Volatility
| ENZY BTA volatility | |
|---|---|
| ENZY BTA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ENZY BTA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ENZY BTA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 18 | Claus Egstrand | www.enzymatica.se |
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that prevents common cold and reduces the duration of illness. It also provides enzyme formulations.
Enzymatica AB (publ) Fundamentals Summary
| ENZY BTA fundamental statistics | |
|---|---|
| Market cap | kr538.76m |
| Earnings (TTM) | -kr49.73m |
| Revenue (TTM) | kr50.90m |
10.6x
P/S Ratio-10.8x
P/E RatioIs ENZY BTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENZY BTA income statement (TTM) | |
|---|---|
| Revenue | kr50.90m |
| Cost of Revenue | kr19.04m |
| Gross Profit | kr31.86m |
| Other Expenses | kr81.59m |
| Earnings | -kr49.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 09, 2024
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 62.59% |
| Net Profit Margin | -97.69% |
| Debt/Equity Ratio | 34.1% |
How did ENZY BTA perform over the long term?
See historical performance and comparison